DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND LEDIPASVIR IN TABLET DOSAGE FORM by M.Prasanthi Evangelin*, S.Manohar Babu, Konda Ravi Kumar
IAJPS 2017, 4 (12), 4815-4821                          M.Prasanthi et al                          ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 4815 
 
 CODEN [USA]: IAJPBB                   ISSN: 2349-7750 
 
  INDO AMERICAN JOURNAL OF 
 PHARMACEUTICAL SCIENCES 
 
                  
 
 
Available online at: http://www.iajps.com                           Research Article 
 
DEVELOPMENT AND VALIDATION OF STABILITY 
INDICATING RP-HPLC METHOD FOR SIMULTANEOUS 
ESTIMATION OF SOFOSBUVIR AND LEDIPASVIR IN TABLET 
DOSAGE FORM 
M.Prasanthi Evangelin*1, S.Manohar Babu2, Konda Ravi Kumar3 
*1, 2 SIMS College of Pharmacy, Mangaldas Nagar, Guntur, India. 
2 Hindu College of Pharmacy, Amaravathi Road, Guntur, A.P, India. 
Abstract: 
Simple, specific, accurate and precise reversed phase high pressure liquid chromatographic method has been developed 
for the simultaneous determination of Sofosbuvir and Ledipasvir in tablet dosage form by reversed phase C18 column 
(Kromasil C18 5μ, 250 mm x 4.6 mm). The sample was analyzed using 0.1% OPA: Acetonitrile in the ratio of 55:45 as a 
mobile phase at a flow rate of 1.0 ml/min and detection at 230 nm. Calibration curves were linear with correlation 
coefficient (r2) 0.999 over a concentration range of 100-600 µg/mL for Sofosbuvir and 0.999 over a concentration 
range of 22.5-135 µg/mL for Ledipasvir. The retention time was found to be 6 min. The mean recoveries were found to 
be 99.10% and 99.30% for Sofosbuvir and Ledipasvir respectively. The relative standard deviation (RSD) was found to 
be < 2.0% for both drugs. The proposed method was validated and successfully applied to the estimation of Sofosbuvir 
and Ledipasvir in tablet dosage form. 
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INTRODUCTION: 
Reverse phase is the choice for the majority of 
samples, but if acidic or basic analytes [1-3] are present 
then reverse phase ion suppression (for weak acids or 
bases) or reverse phase ion pairing should be used. The 
stationary phase should be C18 bonded[4,5]. 
Sofosbuvir is a prodrug nucleotide analog used as part 
of combination therapy to treat hepatitis C virus (HCV) 
infection or to treat co-infection of HIV and HCV.  
 
Sofosbuvir and other nucleotide inhibitors of the HCV 
RNA [6] polymerase exhibit a very high barrier to 
resistance development. Sofosbuvir has become 
available as a fixed dose drug combination product 
with ledipasvir (tradename Harvoni) used for the 
treatment of chronic Hepatitis C, an infectious liver 
disease caused by infection with Hepatitis C Virus 
(HCV). Ledipasvir is previously known as GS-5885, is 
an inhibitor of the Hepatitis C Virus (HCV) NS5A 
protein required for viral RNA replication and 
assembly of HCV virions.  
 
Ledipasvir is available as a fixed dose drug 
combination product [7,8] with sofosbuvir (tradename 
Harvoni) used for the treatment of chronic Hepatitis C, 
an infectious liver disease caused by infection with 
Hepatitis C Virus (HCV). Approved in October 2014 
by the FDA, ledipasvir and sofosbuvir are direct-acting 
antiviral agents indicated for the treatment of HCV 
genotype 1 with or without cirrhosis. Combination of 
these two drugs (Sofosbuvir 400mg and Ledipasvir 
90mg is available in pharmacy under the brand name of 
Myhep Lvir, Ledifos tablet, Heterosofir plus and 
Hepcinat lp tablet. The chemical structures of both 
drugs were shown in Fig.1. 
 
A 
      
B 
Fig.1: Chemical Structures of Sofosbuvir [A] and 
Ledipasvir [B] 
Literature survey revealed that there are only three 
HPLC methods [9-11] have been published regarding 
this research work. The present study aimed to develop 
a simple, sensitive, less retention time and accurate RP-
HPLC method for the simultaneous estimation of 
sofosbuvir and ledipasvir in bulk and tablet dosage 
forms with high sensitivity, selectivity and stability that 
can be used for the routine analysis. 
 
MATERIALS AND METHODS: 
Chemicals and Reagents 
Pure standard samples of sofosbuvir and ledipasvir 
were obtained as gifted samples from Rhodes 
Pharmaceuticals Ltd. and its marketed formulations in 
the brand name of Harvoni [Label claim containing 
sofosbuvir 75mg and ledipasvir 325 mg] were procured 
from local pharmacy. Water (HPLC-Grade), 
Acetonitrile (HPLC-Grade; Rankem) and Methanol 
(HPLC-Grade Rankem), ortho phosphate buffer, 
Ortho-phosphoric acid (Rankem).  All dilutions were 
performed in standard class-A, volumetric glassware.  
 
Instrumentation 
The present assay was carried out on a Waters HPLC 
system [Model: 2695] equipped with 2487 photodiode 
array detector, automated sample injector and a column 
Kromasil C18 (250mmx4.6mm I.D; particle size 5μm) 
respectively. Electronic Balance [Denver] and Ultra-
Sonicator [SE60US; BVK enterprises] were also used 
in the present assay. The output of signal was 
monitored and integrated using waters Empower 2 
software.  
 
Buffer preparation 
0.1%OPA Buffer:1ml of ortho phosphoric acid was 
diluted to 1000ml with HPLC grade water. 
Mobile phase preparation 
Prepare a filtered and degassed mixture of Buffer (pH -
2.0), 0.1% OPA: Acetonitrile (55:45%). 
 
Diluent preparation 
Mobile phase is used as diluent. 
 
Standard preparation 
 Accurately weighed 40mg of Sofosbuvir, 9mg of 
Ledipasvir and transferred to 10ml flasks and 3/4th of 
diluents was added to these flask and sonicated for 10 
minutes. Flask were made up with diluents and labeled 
as Standard stock solution. (40µg/ml of Sofosbuvir and 
2500µg/ml Ledipasvir). 
 
Sample preparation 
5 tablets were weighed and the average weight of each 
tablet was calculated, then the weight equivalent to 1 
tablet was transferred into a 100ml volumetric flask, 
50ml of diluents was added and sonicated for 25 min, 
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further the volume was made up with diluent and 
filtered by HPLC filters (40µg/ml of Sofosbuvir and 
2500µg/ml of Ledipasvir). 
 
RESULTS AND DISCUSSION: 
Method development 
Initial trials were carried by the author in developing 
the proposed RP-HPLC method. The mobile phase was 
chosen after several trials with methanol, acetonitrile, 
water and buffer solutions in various proportions and at 
different pH values. A mobile phase consisting of 0.1% 
OPA buffer (pH -2.0) and acetonitrile (55:45 v/v) was 
selected to achieve maximum separation and 
sensitivity. Flow rates between 0.5 and 1.5/min were 
studied. A flow rate of 1.0 ml/min at ambient 
temperature gave an optimal signal to noise ratio with a 
reasonable separation time. Using a Kromasil C18 
column, the run time of analysis was 6 min. Detection 
wavelength of 230 nm was chosen for the analysis. A 
typical chromatogram for simultaneous estimation of 
sofosbuvir and ledipasvir obtained by using a mobile 
phase was shown in Fig.2. 
 
Fig.2: Typical chromatogram of standard solution (sofosbuvir and ledipasvir) 
 
Chromatographic conditions 
The isocratic mobile phase consisted of 0.1% OPA 
buffer (pH -2.0) and Acetonitrile (55:45 v/v), flowing 
through the Kromosil C18 column (make: 250 mmx4.6 
mm i.d; particle size 5μm) at a constant flowrate of 1.0 
ml/min at ambient column temperature. The mobile 
phase was pumped through the column at a flowrate of 
1.0ml/min with a sample injection volume of 10μl. 
Detection of the analytes (sofosbuvir and ledipasvir) 
was carried out at a wavelength of 230 nm. 
 
Method validation 
The proposed RP-HPLC method was validated, in 
accordance with USP guidelines for system. 
 
System suitability 
RP-HPLC method System performance parameters 
were determined by analyzing standard working 
solutions of sofosbuvir and ledipasvir. The 
chromatographic parameters, such as number of 
theoretical plates (n), resolution (Rs), USP plate count 
and USP tailing were determined. The results are 
shown in Table.1, indicating the good performance of 
the system. 
 
 
 
 
Table1: System suitability data of sofosbuvir and 
ledipasvir 
S.N
o 
Sample 
name 
RT USP Plate 
count 
USP 
tailing 
1. Injection 1 
(sofosbuvir) 
2.442 7792 1.08 
2. Injection 1 
(Ledipasvir) 
3.072 11272 0.94 
 
Specificity 
Blank and placebo interference 
The interference of blank and placebo with the elution 
of the present cited drugs solutions of diluents and 
placebo were injected into the chromatographic system 
with the mentioned chromatographic conditions and 
their respective chromatograms were recorded. From 
the reported chromatograms it was observed that the 
placebo and blank showed no peaks at the retention 
time of sofosbuvir and ledipasvir peak indicating that 
the diluent and placebo solutions used in standard and 
sample preparations did not interfered in assay of 
sofosbuvir and ledipasvir respectively. 
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Linearity & Detector response 
The linearity of the proposed method was accessed by 
calculating slope, intercept and correlation coefficient 
[r2] of standard curve. Sofosbuvir and ledipasvir 
showed a linearity range in between 100-600 and 22.5-
135μg/ml  respectively and the slope and intercept of 
the calibration plot of sofosbuvir and ledipasvir were 
2966x+2193 and 41019x + 15917 with correlation 
coefficients obtained was greater than 0.999 
respectively. The linearity results of both the drugs 
were shown in Tab.2 and Linearity curves of 
sofosbuvir and ledipasvir were depicted in Fig.3. 
 
Table 2: Linearity results for Sofosbuvir and Ledipasvir 
  
Sofosbuvir Ledipasvir 
Conc. (μg/ml) Peak area Conc.(μg/ml) Peak area 
0 0 0 0 
100 293334 22.5 937588 
200 597524 45 1888960 
300 892905 67.5 2781827 
400 1192639 90 3686223 
500 1507994 112.5 4674738 
600 1760574 135 5523393 
 
               
                                A                                                                                                                   B 
 
Fig.3: Linear calibration plot for Sofosbuvir (A) and Ledipasvir (B) 
 
Sensitivity 
The limit of detection (LOD) and limit of 
quantification (LOQ) were established at signal-to 
noise ratio of 3:1 and 10:1 respectively. The LOD of 
sofosbuvir and ledipasvir was found to be 0.02μg /ml 
& 0.28μg /ml respectively. The LOQ of sofosbuvir and 
ledipasvir was found to be 0.07 μg /ml & 0.85μg / ml 
respectively. 
 
Precision 
The precision of sofosbuvir and ledipasvir by proposed 
RP-HPLC method was ascertained by replicate 
analysis of homogeneous samples of Tablet powder. 
Intermediate precision of the present RP-HPLC method 
was studied by intra-day variation of the method was 
carried out. The results were given in Tab.3 and the 
low % RSD values of within a day for sofosbuvir and 
ledipasvir revealed that the proposed method is highly 
precise. 
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Table 3: System precision table of Sofosbuvir and Ledipasvir 
 
S.No  Area of Sofosbuvir Area of  Ledipasvir 
1.  
1145677 3578272 
2.  
1152265 3587779 
3.  
1154492 3608922 
4.  
1148949 3624217 
5.  
1156499 3600959 
6.  
1160648 3601532 
Mean  
1153088 3600280 
S.D  
5357.08 16064.4 
%RSD  
0.5 0.4 
 
Accuracy 
The accuracy of the proposed method for sofosbuvir 
and ledipasvir was assessed by recovery studies at 
three different levels i.e. 50%, 100%, 150%. The 
recovery studies were carried out in triplicate by 
adding Known amount of standard solution of 
sofosbuvir and ledipasvir to preanalysed tablet 
solutions. The resulting solutions were then reanalysed 
by proposed method and the results are represented in 
Tab.4. The percentage recoveries were found in the 
range of 98.82 to 100.9% for sofosbuvir and 98.50 to 
100.9% for ledipasvir respectively revealing that the 
developed RP-HPLC method was found to be accurate. 
 
Table 4: Results of Accuracy for Sofosbuvir and Ledipasvir 
S.No Accuracy level  Injection Sofosbuvir Ledipasvir 
% Recovery % Recovery 
1. 50% 
1 
98.82 98.50 
2 
100.48 98.18 
3 
98.02 98.51 
2. 100% 
1 98.63 100.44 
2 99.25 101.29 
3 100.09 100.65 
3. 150% 
1 100.34 98.19 
2 99.68 98.82 
3 99.01 99.08 
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Table 5: Robustness data for Sofosbuvir and Ledipasvir 
 
S.No Condition % RSD of 
Sofosbuvir 
% RSD of Ledipasvir 
1 Flow rate (-) 1.1ml/min 0.5 0.4 
2 Flow rate (+) 1.3ml/min 0.5 0.7 
3 Mobile phase (-) 35B:65A 0.5 0.4 
4 Mobile phase (+) 45B:55A 0.5 0.5 
5 Temperature (-) 25°C 0.3 0.3 
6 Temperature (+) 35°C 0.1 0.1 
 
Table 6: Assay of Sofosbuvir and ledipasvir in Formulation 
Drug name 
(Harvoni tablets) 
Quantity label 
claim(mg) 
Quantity found± SD %Assay ± SD 
Sofosbuvir 75 mg 1143799 ±0.50 99.10 ± 0.46 
Ledipasvir 325 mg 3567195 ±0.30 98.98 ± 0.46 
 
 
Robustness 
The robustness of the developed method was evaluated 
by altering few experimental conditions and evaluating 
the resolution between two adjacent peaks of 
sofosbuvir and ledipasvir. The data results were shown 
in Tab.5. 
Formulation assay 
The validated method was applied on commercially 
available Harvoni tablets. The results of the assay 
undertaken yielded 99.10% and 99.30% of the label 
claim for sofosbuvir and ledipasvir. Results of the 
assay indicated that the method is quite selective for 
the analysis of Harvoni without interference from the 
excipients used to formulate and produce these tablets. 
The results were displayed in Tab.6 respectively. 
 
CONCLUSION:  
It was concluded that the proposed new RP-HPLC 
method developed for the quantitative determination of 
Sofosbuvir and ledipasvir in bulk as well as in its 
formulations was simple, selective, sensitive, accurate, 
precise and rapid. The method was proved to be 
superior to most of the reported methods. The mobile 
phase was simple to prepare and economical.     The 
sample recoveries in the formulation were in good 
agreement with their respective label claims and they 
suggested non-interference of formulation excipients in 
the estimation. Hence the method can be easily adopted 
as an alternative method to report routine estimation of 
Sofosbuvir and ledipasvir depending upon the 
availability of chemicals and nature of other 
ingredients present in the sample. The method was 
validated as per ICH guidelines, and validation 
acceptance criteria were met in all cases. Application 
of this method for estimation of Sofosbuvir and 
ledipasvir from tablet dosage form and stressed 
samples showed that neither the degradation products 
nor the excipients interfered in the estimation of drug. 
Hence, this method was specific, stability-indicating 
and can be successfully used for the estimation of drug 
in bulk and pharmaceutical dosage form. 
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